Fox Chase Cancer Center News

PHILADELPHIA (March 1, 2019) —Patients, survivors, caregivers and advocates join together this March for National Colorectal Cancer Awareness Month. 

The TAILORx trial found that thousands of women with a certain type of early-stage hormone-positive, HER-2 negative breast cancer did just as well with hormone therapy alone. 

SAN MATEO, CA, February 19, 2019 — Fox Chase Cancer Center and MORE Health, a global healthcare company, announced a cutting-edge partnership that gives patients from across the world access to the nationally ranked physicians of Fox Chase Cancer Center through MORE Health’s Physician Collaboration Platform™.

PHILADELPHIA (February 18, 2019) — John Krais, PhD, a postdoctoral researcher at Fox Chase Cancer Center, recently received a two-year, $75,000 grant from the Ovarian Cancer Research Alliance (OCRA) for his investigation into DNA repair processes in BRCA1 mutant cancers.

PHILADELPHIA (February 15, 2019) – A board-certified psychiatrist, Suzanne Doubrava, MD, has done extensive research on the effects of long-term psychodynamic psychotherapy for end-stage cancer patients. She comes to Fox Chase after several years in private practice.

PHILADELPHIA (February 13, 2019) — Fox Chase Cancer Center researchers have published a groundbreaking study that describes for the first time the mechanisms of how the amount of amino acid phenylalanine (Phe) is controlled in blood. Accumulation of Phe can cause phenylketonuria (PKU), a rare genetic condition that can result in permanent neurological damage as well as behavioral abnormalities if not properly managed.

PHILADELPHIA (February 7, 2019) — Siddharth Balachandran, PhD, co-leader of the Blood Cell Development and Function Program at Fox Chase Cancer Center, was recently awarded a grant from the National Institute on Aging to conduct research on the process of cell death as a response to external trauma or disease. 

PHILADELPHIA (February 4, 2019) — By diving deep into data about more than 1,300 past kidney cancer cases, Fox Chase Cancer Center researchers concluded that there is no compelling cancer-related reason to remove an entire kidney solely based on a tumor’s location in the hilum.